Johnson & Johnson (NYSE:JNJ) Shares Acquired by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 491,117 shares of the company’s stock after buying an additional 6,481 shares during the quarter. Johnson & Johnson accounts for 1.1% of Oppenheimer Asset Management Inc.’s portfolio, making the stock its 11th largest position. Oppenheimer Asset Management Inc.’s holdings in Johnson & Johnson were worth $77,690,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Christopher J. Hasenberg Inc acquired a new stake in Johnson & Johnson during the 1st quarter valued at $31,000. Keener Financial Planning LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter worth about $40,000. WFA Asset Management Corp boosted its holdings in Johnson & Johnson by 61.4% in the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after purchasing an additional 97 shares during the last quarter. Vermillion & White Wealth Management Group LLC acquired a new stake in Johnson & Johnson during the 4th quarter valued at approximately $44,000. Finally, Disciplined Equity Management Inc. purchased a new stake in Johnson & Johnson during the 4th quarter worth approximately $45,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on JNJ shares. The Goldman Sachs Group started coverage on shares of Johnson & Johnson in a research report on Thursday, May 30th. They set a “neutral” rating and a $160.00 price target for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research report on Monday, June 17th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Monday, July 1st. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Sunday, June 30th. Finally, Morgan Stanley decreased their target price on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 17th. Eight research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $174.07.

Johnson & Johnson Stock Performance

Shares of JNJ stock traded up $0.18 during trading hours on Friday, reaching $149.88. The stock had a trading volume of 5,336,394 shares, compared to its average volume of 5,911,580. The firm has a market capitalization of $360.71 billion, a PE ratio of 9.34, a price-to-earnings-growth ratio of 2.50 and a beta of 0.52. The firm has a 50-day simple moving average of $147.94 and a 200-day simple moving average of $153.48. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $175.97. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The company had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. During the same quarter last year, the business earned $2.68 earnings per share. Johnson & Johnson’s revenue was up 2.3% compared to the same quarter last year. As a group, equities analysts forecast that Johnson & Johnson will post 10.5 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were issued a $1.24 dividend. The ex-dividend date was Monday, May 20th. This represents a $4.96 annualized dividend and a yield of 3.31%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.